Serum bone specific alkaline phosphatase and urinary deoxypyridinoline in postmenopausal osteoporosis.

H. M. Nawawi, T. N. Yazid, N. M. Ismail, A. R. Mohamad, Ima Nirwana Soelaiman, B. A. Khalid

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The objectives of this study were to: (i) evaluate the diagnostic sensitivity and specificity of the biochemical bone markers: serum total alkaline phosphatase (TALP), bone specific alkaline phosphatase (BSALP) and urinary deoxypyridinoline (Dpyr) in postmenopausal osteoporosis, (ii) compare the bone turnover of postmenopausal osteoporotic patients without and with hormone replacement therapy (HRT) against controls and (iii) identify the correlation between these bone markers and bone mineral density (BMD). We examined 42 postmenopausal women with BMD proven osteoporosis and 35 control subjects. Serum TALP, BSALP and urinary Dpyr were measured. All three biochemical bone markers showed comparable moderate diagnostic sensitivity but Dpyr had the highest diagnostic specificity. There were significantly higher serum TALP, BSALP and urinary Dpyr levels in non-HRT treated patients compared to controls (p<0.005, <0.0001 and <0.005 respectively). There were no significant differences in the levels of all three bone markers between HRT treated patients and control subjects. There was no significant correlation between TALP, BSALP or Dpyr and BMD in both controls and patients. In conclusion, the biochemical bone markers are not useful in diagnosis of postmenopausal osteoporosis but may have a role in monitoring progress and response to treatment. HRT treatment reduces bone turnover of postmenopausal osteoporosis.

Original languageEnglish
Pages (from-to)79-88
Number of pages10
JournalThe Malaysian journal of pathology
Volume23
Issue number2
Publication statusPublished - 2001

Fingerprint

Postmenopausal Osteoporosis
Alkaline Phosphatase
Bone and Bones
Serum
Hormone Replacement Therapy
Bone Density
Bone Remodeling
Biomarkers
deoxypyridinoline
Osteoporosis
Therapeutics
Sensitivity and Specificity

Cite this

Serum bone specific alkaline phosphatase and urinary deoxypyridinoline in postmenopausal osteoporosis. / Nawawi, H. M.; Yazid, T. N.; Ismail, N. M.; Mohamad, A. R.; Soelaiman, Ima Nirwana; Khalid, B. A.

In: The Malaysian journal of pathology, Vol. 23, No. 2, 2001, p. 79-88.

Research output: Contribution to journalArticle

Nawawi, H. M. ; Yazid, T. N. ; Ismail, N. M. ; Mohamad, A. R. ; Soelaiman, Ima Nirwana ; Khalid, B. A. / Serum bone specific alkaline phosphatase and urinary deoxypyridinoline in postmenopausal osteoporosis. In: The Malaysian journal of pathology. 2001 ; Vol. 23, No. 2. pp. 79-88.
@article{e5476032f39843e6849196006490549d,
title = "Serum bone specific alkaline phosphatase and urinary deoxypyridinoline in postmenopausal osteoporosis.",
abstract = "The objectives of this study were to: (i) evaluate the diagnostic sensitivity and specificity of the biochemical bone markers: serum total alkaline phosphatase (TALP), bone specific alkaline phosphatase (BSALP) and urinary deoxypyridinoline (Dpyr) in postmenopausal osteoporosis, (ii) compare the bone turnover of postmenopausal osteoporotic patients without and with hormone replacement therapy (HRT) against controls and (iii) identify the correlation between these bone markers and bone mineral density (BMD). We examined 42 postmenopausal women with BMD proven osteoporosis and 35 control subjects. Serum TALP, BSALP and urinary Dpyr were measured. All three biochemical bone markers showed comparable moderate diagnostic sensitivity but Dpyr had the highest diagnostic specificity. There were significantly higher serum TALP, BSALP and urinary Dpyr levels in non-HRT treated patients compared to controls (p<0.005, <0.0001 and <0.005 respectively). There were no significant differences in the levels of all three bone markers between HRT treated patients and control subjects. There was no significant correlation between TALP, BSALP or Dpyr and BMD in both controls and patients. In conclusion, the biochemical bone markers are not useful in diagnosis of postmenopausal osteoporosis but may have a role in monitoring progress and response to treatment. HRT treatment reduces bone turnover of postmenopausal osteoporosis.",
author = "Nawawi, {H. M.} and Yazid, {T. N.} and Ismail, {N. M.} and Mohamad, {A. R.} and Soelaiman, {Ima Nirwana} and Khalid, {B. A.}",
year = "2001",
language = "English",
volume = "23",
pages = "79--88",
journal = "Malaysian Journal of Pathology",
issn = "0126-8635",
publisher = "Malaysian Society of Pathologists",
number = "2",

}

TY - JOUR

T1 - Serum bone specific alkaline phosphatase and urinary deoxypyridinoline in postmenopausal osteoporosis.

AU - Nawawi, H. M.

AU - Yazid, T. N.

AU - Ismail, N. M.

AU - Mohamad, A. R.

AU - Soelaiman, Ima Nirwana

AU - Khalid, B. A.

PY - 2001

Y1 - 2001

N2 - The objectives of this study were to: (i) evaluate the diagnostic sensitivity and specificity of the biochemical bone markers: serum total alkaline phosphatase (TALP), bone specific alkaline phosphatase (BSALP) and urinary deoxypyridinoline (Dpyr) in postmenopausal osteoporosis, (ii) compare the bone turnover of postmenopausal osteoporotic patients without and with hormone replacement therapy (HRT) against controls and (iii) identify the correlation between these bone markers and bone mineral density (BMD). We examined 42 postmenopausal women with BMD proven osteoporosis and 35 control subjects. Serum TALP, BSALP and urinary Dpyr were measured. All three biochemical bone markers showed comparable moderate diagnostic sensitivity but Dpyr had the highest diagnostic specificity. There were significantly higher serum TALP, BSALP and urinary Dpyr levels in non-HRT treated patients compared to controls (p<0.005, <0.0001 and <0.005 respectively). There were no significant differences in the levels of all three bone markers between HRT treated patients and control subjects. There was no significant correlation between TALP, BSALP or Dpyr and BMD in both controls and patients. In conclusion, the biochemical bone markers are not useful in diagnosis of postmenopausal osteoporosis but may have a role in monitoring progress and response to treatment. HRT treatment reduces bone turnover of postmenopausal osteoporosis.

AB - The objectives of this study were to: (i) evaluate the diagnostic sensitivity and specificity of the biochemical bone markers: serum total alkaline phosphatase (TALP), bone specific alkaline phosphatase (BSALP) and urinary deoxypyridinoline (Dpyr) in postmenopausal osteoporosis, (ii) compare the bone turnover of postmenopausal osteoporotic patients without and with hormone replacement therapy (HRT) against controls and (iii) identify the correlation between these bone markers and bone mineral density (BMD). We examined 42 postmenopausal women with BMD proven osteoporosis and 35 control subjects. Serum TALP, BSALP and urinary Dpyr were measured. All three biochemical bone markers showed comparable moderate diagnostic sensitivity but Dpyr had the highest diagnostic specificity. There were significantly higher serum TALP, BSALP and urinary Dpyr levels in non-HRT treated patients compared to controls (p<0.005, <0.0001 and <0.005 respectively). There were no significant differences in the levels of all three bone markers between HRT treated patients and control subjects. There was no significant correlation between TALP, BSALP or Dpyr and BMD in both controls and patients. In conclusion, the biochemical bone markers are not useful in diagnosis of postmenopausal osteoporosis but may have a role in monitoring progress and response to treatment. HRT treatment reduces bone turnover of postmenopausal osteoporosis.

UR - http://www.scopus.com/inward/record.url?scp=0035554082&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035554082&partnerID=8YFLogxK

M3 - Article

C2 - 12166596

AN - SCOPUS:0035554082

VL - 23

SP - 79

EP - 88

JO - Malaysian Journal of Pathology

JF - Malaysian Journal of Pathology

SN - 0126-8635

IS - 2

ER -